Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Change in Receivables (2020 - 2022)

Historic Change in Receivables for 4D Molecular Therapeutics (FDMT) over the last 3 years, with Q1 2022 value amounting to -$47000.0.

  • 4D Molecular Therapeutics' Change in Receivables rose 9097.89% to -$47000.0 in Q1 2022 from the same period last year, while for Dec 2022 it was -$47000.0, marking a year-over-year increase of 9673.38%. This contributed to the annual value of -$47000.0 for FY2022, which is 9673.38% up from last year.
  • Per 4D Molecular Therapeutics' latest filing, its Change in Receivables stood at -$47000.0 for Q1 2022, which was up 9097.89% from -$744000.0 recorded in Q4 2021.
  • 4D Molecular Therapeutics' 5-year Change in Receivables high stood at $590000.0 for Q4 2020, and its period low was -$744000.0 during Q4 2021.
  • Its 3-year average for Change in Receivables is -$108666.7, with a median of -$99000.0 in 2020.
  • The largest annual percentage gain for 4D Molecular Therapeutics' Change in Receivables in the last 5 years was 26754.97% (2021), contrasted with its biggest fall of 42626.26% (2021).
  • Quarter analysis of 3 years shows 4D Molecular Therapeutics' Change in Receivables stood at $590000.0 in 2020, then plummeted by 226.1% to -$744000.0 in 2021, then soared by 93.68% to -$47000.0 in 2022.
  • Its Change in Receivables stands at -$47000.0 for Q1 2022, versus -$744000.0 for Q4 2021 and -$427000.0 for Q3 2021.